

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1615
Examiner Name	Jones, Dameron

Sheet 1 of 1

Attorney Docket No: 295.044US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
JS	WO-PCT/AU91/00155	10/31/1991	Turner, Harvey J., et al.	—	—	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JS		The Journal of the American Society of Hematology, Vol. 94, No. 10, Suppl 1 (Part 1 of 2), (11-15-1999),	✓
JS		"VII International Multiple Myeloma Workshop", Abstract Book, Stockholm Sweden, (09-1/5-1999), 117	✓
JS		TURNER, J. H., et al., "Samarium - 153 EDTMP therapy of disseminated skeletal metastasis", Eur J. Nucl Med (1989) 15, (1989), 784-795	✓

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached



Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/014,335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616
Examiner Name	Jones, Dameron

Sheet 1 of 1

Attorney Docket No: 295.044US1




US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
--------------------	---------------------	------------------	---	-------	----------	----------------------------


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	KABACHNIK et al., "Synthesis and Acid-Base and Complex-Forming Properties of 1,4,7,10 - Tetrakis (dihydroxyphosphorylmethyl) - 1,4,7,10 - tetraazacyclododecane", <u>Bulletin of the Academy of Sciences of the USSR; Division of Chemical Science</u> , <u>33</u> , 777-782 (1984).
	KAPLAN et al., "Therapy of Carcinoma of the Prostate Metastatic to Bone with P32 Labeled Condensed Phosphate", <u>The Journal of Nuclear Medicine</u> , <u>1</u> , 1-13 (1960).
	SCHMIDT et al., "89-Sr for the Treatment of Incurable Pain in Patient with Neoplastic Osseous Infiltrations", <u>Int. J. Clin. Pharmacol</u> , <u>9</u> , 199-205 (1974).

EXAMINER



DATE CONSIDERED



Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number 10/014,335
Filing Date December 11, 2001
First Named Inventor Fritzberg, Alan
Group Art Unit 1616
Examiner Name Jones, Dameron

Sheet 1 of 2

Attorney Docket No: 295.044US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
DP	4,897,255	01/30/1990	Fritzberg et al.	424	1.1	06/19/1987
	5,393,512	02/28/1995	Vanderheyden et al.	424	1.53	09/20/1993
	5,679,318	10/21/1997	Vanderheyden et al.	424	1.11	11/21/1994
DP	5,756,685	05/26/1998	Fritzberg et al.	530	391.5	07/12/1996

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
---------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DP	ANDERSON et al., "High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases", <u>Journal of Clinical Oncology</u> , 20, 189-196 (2002).
✓	BENSINGER et al., "166Ho-DOTMP and High-Dose Melphalan before Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Abstract P287; IXth International Workshop on Multiple Myeloma (2003).
✓	BENSINGER et al., "Skeletal Targeted Radiotherapy (STR) with 166Ho-DOTMP plus Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma(MM)", <u>Meeting Proceedings of ASCO</u> , 22, ASCO Annual Meeting, May 2003; Abstract Number 3346, 833 (2003).
✓	BREITZ et al., "Dosimetry of High Dose Skeletal Targeted Radiotherapy (STR) with 166-Ho-DOTMP", <u>Cancer Biotherapy and Radiopharmaceuticals</u> , 18, 225-230 (2003).
x	DISPENZIERI et al., "A Phase I Study of a Conditioning Regimen for Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM): 153Samarium Ethylenediaminetetramethylenephosphonate (153SM-EDMPT) and Melphalan", <u>Blood</u> , 96, Abstract 2397, 558a (2000).
x	DISPENZIERI et al., "A Phase I/II Dose Escalation Study of 153-Samarium EDTMP (153-Sm-EDMTP) with Fixed Dose Melphalan Peripheral Stem Cell Transplantation (PBSCT) for Multiple Myeloma (MM)", <u>Blood</u> , 98, Abstract 2855, 682a-683a (2001).
x	GIRALT et al., "166Ho-DOTMP Plus Melphalan Followed by Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma: Results of Two Phase I/II Trials", <u>Blood</u> , Blood First Edition Paper; DOI 10.1182/2002-10-3250, 1-38 (2003).
✓	GIRALT et al., "Long-Term Follow-Up of 83 Patients with Multiple Myeloma (MM) Treated on a Phase I-II Study of Skeletal Targeted Radiotherapy (STR) Using 166Ho-DOTMP Plus Melphalan with or without Total Body Irradiation (TBI) and Autologous Hematopoietic Stem Cell ...", <u>Blood</u> , 100, 44th Annual Meeting of the American Society of Hematology; Abstract 670, 179a (2002).
DP	HOGAN et al., "Successful Treatment of POEMS Syndrome with Autologous Hematopoietic Progenitor Cell Transplantation", <u>Bone Marrow Transplantation</u> , 28, 305-309 (2001)

EXAMINER

DATE CONSIDERED

10/7/03

Substitute Disclosure Statement Form (PTO-1449)


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/014,335
Filing Date	December 11, 2001
First Named Inventor	Fritzberg, Alan
Group Art Unit	1616
Examiner Name	Jones, Dameron

Sheet 2 of 2

Attorney Docket No: 295.044US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RA	RAJENDRAN et al., "High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation", <u>J Nucl Med</u> , <u>43</u> , 1383-1390 (2002).
WJ	WISEMAN et al., "Bone Targeted Radioisotope Therapy for Treatment of Multiple Myeloma and Bone Tumors", <u>International Journal of Cancer</u> , <u>13</u> , Abstract O 109, 104 (2002).
WJ	WISEMAN et al., "Residual Whole Body 153Samarium Activity Predicts for Successful Autologous Peripheral Blood Progenitor Cell (PBPC) Engraftment Following High Dose 153Samarium Ethylene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) Targeted Radiotherapy", <u>Blood</u> , <u>96</u> , Abstract 1811, 421 (2000). X

EXAMINER

DQ Jones

DATE CONSIDERED

10/12/03

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached